This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Novo Nordisk (NVO) settling at $97.12, representing a +0.86% change from its previous close.
Take the Zacks Approach to Beat the Market: Novo Nordisk, Amgen, Fabrinet in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Pharma Stock Roundup: JNJ Posts Upbeat Q3 Earnings, PFE, NVO Revise 2023 View
by Kinjel Shah
J&J (JNJ) reports strong third-quarter results. Merck's (MRK) new deal with Japan's Daiichi Sankyo to jointly develop the latter's three DXd ADC candidates.
Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B
by Zacks Equity Research
Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $101.15 in the latest trading session, marking a -0.97% move from the prior day.
Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain
by Zacks Equity Research
Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.
Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Pharma Stock Roundup: LLY Meets IBD Study Goal, PFE, MRK Give Cancer Pipeline Updates
by Kinjel Shah
Eli Lilly's (LLY) mirikizumab meets the main goals in a Crohn's disease study. PFE, MRK and JNJ provide updates on cancer drugs in their pipeline.
Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study
by Zacks Equity Research
Eli Lilly's (LLY) Mounjaro is also being evaluated in clinical studies for patients who are obese or overweight and have CKD. Investors are probably expecting similar success with Mounjaro's CKD study.
Zacks Investment Ideas feature highlights: Nvidia, Tesla and Novo Nordisk
by Zacks Equity Research
Nvidia, Tesla and Novo Nordisk are part of the Zacks Investment Ideas article.
The 3 Widest Competitive Moats on Wall Street
by Andrew Rocco
Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.
Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update
by Zacks Equity Research
Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.
New Strong Sell Stocks for October 11th
by Zacks Equity Research
NVO, MT and PRPL have been added to the Zacks Rank #5 (Strong Sell) List on October 11, 2023.
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $92.06, denoting a -0.07% change from the preceding trading day.
Beat the Market the Zacks Way: UnitedHealth, Novo Nordisk, Check Point Software in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
by Zacks Equity Research
Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.
Implied Volatility Surging for Novo Nordisk (NVO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Novo Nordisk (NVO) stock based on the movements in the options market lately.
Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $91.80, marking a +0.95% move from the previous day.
ACM Research and Advance Auto Parts have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
ACM Research and Advance Auto Parts have been highlighted as Zacks Bull and Bear of the Day.
3 Stocks to Focus on as Demand for Obesity Drugs Booms
by Kinjel Shah
With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $91.79, marking a +0.72% move from the previous day.
Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs
by Zacks Equity Research
Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.
Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $94.73, moving +1.29% from the previous trading session.
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?